NCT06675864 - Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

June 13, 2030

Study Completion Date

June 13, 2030

Conditions

Progressive Multiple Sclerosis

Interventions

BIOLOGICAL

rapcabtagene autoleucel (YTB323)

CAR-T cell suspension for intravenous infusion

Trial Locations (15)

1011

RECRUITING

Novartis Investigative Site, Lausanne

2010

RECRUITING

Novartis Investigative Site, Darlinghurst

3004

RECRUITING

Novartis Investigative Site, Melbourne

3010

RECRUITING

Novartis Investigative Site, Bern

8091

RECRUITING

Novartis Investigative Site, Zurich

16132

RECRUITING

Novartis Investigative Site, Genova

20132

RECRUITING

Novartis Investigative Site, Milan

28222

RECRUITING

Novartis Investigative Site, Madrid

29010

RECRUITING

Novartis Investigative Site, Málaga

34090

RECRUITING

Novartis Investigative Site, Montpellier

35000

RECRUITING

Novartis Investigative Site, Rennes

45147

RECRUITING

Novartis Investigative Site, Essen

54035

RECRUITING

Novartis Investigative Site, Nancy

89081

RECRUITING

Novartis Investigative Site, Ulm

G1J 1Z4

RECRUITING

Novartis Investigative Site, Québec